Addimmune, Clinical Stage HIV-Focused Gene Therapy Company, To Go Public Through Business Combination With SPAC 10x Capital Venture Acquisition Corp. III
Addimmune, Clinical Stage HIV-Focused Gene Therapy Company, To Go Public Through Business Combination With SPAC 10x Capital Venture Acquisition Corp. III
專注於HIV的臨床階段基因療法公司Addimmune將通過與SPAC 10x Capital Venture Aquisition Corp. III的業務合併上市
Addimmune, Clinical Stage HIV-Focused Gene Therapy Company, To Go Public Through Business Combination With SPAC 10x Capital Venture Acquisition Corp. III
專注於HIV的臨床階段基因療法公司Addimmune將通過與SPAC 10x Capital Venture Aquisition Corp. III的業務合併上市
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。